{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:00:50Z","timestamp":1787014850190,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":3780,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1111\/j.1523-1755.2005.00461.x","type":"journal-article","created":{"date-parts":[[2005,7,12]],"date-time":"2005-07-12T14:03:59Z","timestamp":1121177039000},"page":"813-817","source":"Crossref","is-referenced-by-count":119,"title":["Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study"],"prefix":"10.1016","volume":"68","author":[{"given":"Chi Chiu","family":"Mok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Hang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Hung","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui Pong","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tak Cheung","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0010","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0015","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.amjmed.2004.04.029","article-title":"Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus","volume":"11","author":"Mok","year":"2004","journal-title":"Am J Med"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0020","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0025","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/art.20364","article-title":"Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis","volume":"50","author":"Mok","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0030","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2-1","article-title":"Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy","volume":"41","author":"Mok","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0035","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003495-200363120-00006","article-title":"Tacrolimus: A further update of its use in the management of organ transplantation","volume":"63","author":"Scott","year":"2003","journal-title":"Drugs"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0040","first-page":"136","article-title":"Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level","volume":"75","author":"Andersson","year":"1992","journal-title":"Immunology"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0045","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00007890-200203150-00021","article-title":"A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years","volume":"73","author":"Vincenti","year":"2002","journal-title":"Transplantation"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0050","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(02)11196-2","article-title":"UK and Republic of Ireland Liver Transplant Study Group. Tacrolimus versus microemulsified ciclosporin in liver transplantation: The TMC randomized controlled trial","volume":"360","author":"O'Grady","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0055","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0041-1345(00)02319-8","article-title":"European Tacrolimus Renal Rejection Study Group. Conversion at first rejection: A prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients","volume":"33","author":"Dudley","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0060","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1097\/00007890-200206150-00019","article-title":"Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production","volume":"73","author":"Jiang","year":"2002","journal-title":"Transplantation"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0896-8411(03)00043-X","article-title":"The role of interleukin-10 in systemic lupus erythematosus","volume":"20","author":"Llorente","year":"2003","journal-title":"J Autoimmun"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0070","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1002\/art.11363","article-title":"Tacrolimus Rheumatoid Arthritis Study Group. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: A double-blind trial","volume":"48","author":"Yocum","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/0090-1229(89)90211-0","article-title":"Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus","volume":"51","author":"Takabayashi","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0080","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1159\/000187375","article-title":"Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL\/MpJ-lpr\/lpr mice","volume":"64","author":"Entani","year":"1993","journal-title":"Nephron"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0085","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5414\/CNP62049","article-title":"Tacrolimus-(FK 506) based immunosuppression in severe systemic lupus erythematosus","volume":"62","author":"Politt","year":"2004","journal-title":"Clin Nephrol"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0090","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/ard.56.11.690","article-title":"Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases","volume":"56","author":"Duddridge","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0095","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/keh325","article-title":"Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: A possible alternative Oxford","volume":"43","author":"Lampropoulos","year":"2004","journal-title":"Rheumatology"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0100","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0105","series-title":"Classification and Atlas of Glomerular Diseases","author":"Churg","year":"1995"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0110","first-page":"1468","article-title":"Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation","volume":"21","author":"Gladman","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0115","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1053\/ajkd.2001.26084","article-title":"Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens","volume":"38","author":"Mok","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0120","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/rheumatology\/37.2.217","article-title":"Clinical efficacy of cyclosporin a neoral in the treatment of pediatric lupus nephritis with heavy proteinuria","volume":"37","author":"Fu","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0125","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/qjmed\/91.8.573","article-title":"Long-term treatment of lupus nephritis with cyclosporin A","volume":"91","author":"Tam","year":"1998","journal-title":"Q J Med"},{"key":"10.1111\/j.1523-1755.2005.00461.x_bb0130","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1191\/096120300680198935","article-title":"Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature","volume":"9","author":"Hallegua","year":"2000","journal-title":"Lupus"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815509034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815509034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T09:24:24Z","timestamp":1648286664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815509034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0085253815509034"],"URL":"https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00461.x","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}